59 related articles for article (PubMed ID: 9177701)
21. Nerve growth factor-induced migration of endothelial cells.
Dollé JP; Rezvan A; Allen FD; Lazarovici P; Lelkes PI
J Pharmacol Exp Ther; 2005 Dec; 315(3):1220-7. PubMed ID: 16123305
[TBL] [Abstract][Full Text] [Related]
22. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
23. Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase.
Woronowicz A; Amith SR; De Vusser K; Laroy W; Contreras R; Basta S; Szewczuk MR
Glycobiology; 2007 Jan; 17(1):10-24. PubMed ID: 16971381
[TBL] [Abstract][Full Text] [Related]
24. TrkA mediates the nerve growth factor-induced intracellular calcium accumulation.
De Bernardi MA; Rabins SJ; Colangelo AM; Brooker G; Mocchetti I
J Biol Chem; 1996 Mar; 271(11):6092-8. PubMed ID: 8626395
[TBL] [Abstract][Full Text] [Related]
25. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
Camoratto AM; Jani JP; Angeles TS; Maroney AC; Sanders CY; Murakata C; Neff NT; Vaught JL; Isaacs JT; Dionne CA
Int J Cancer; 1997 Aug; 72(4):673-9. PubMed ID: 9259409
[TBL] [Abstract][Full Text] [Related]
26. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat.
Owolabi JB; Rizkalla G; Tehim A; Ross GM; Riopelle RJ; Kamboj R; Ossipov M; Bian D; Wegert S; Porreca F; Lee DK
J Pharmacol Exp Ther; 1999 Jun; 289(3):1271-6. PubMed ID: 10336516
[TBL] [Abstract][Full Text] [Related]
27. The use of TrkA-PathHunter assay in high-throughput screening to identify compounds that affect nerve growth factor signaling.
Forsell P; Almqvist H; Hillertz P; Akerud T; Otrocka M; Eisele L; Sun K; Andersson H; Trivedi S; Wollberg AR; Dekker N; Rottici D; Sandberg K
J Biomol Screen; 2013 Jul; 18(6):659-69. PubMed ID: 23458757
[TBL] [Abstract][Full Text] [Related]
28. Characterization of specific binding sites for [3H]-staurosporine on various protein kinases.
Herbert JM; Seban E; Maffrand JP
Biochem Biophys Res Commun; 1990 Aug; 171(1):189-95. PubMed ID: 2393390
[TBL] [Abstract][Full Text] [Related]
29. TrkA antagonists decrease NGF-induced ChAT activity in vitro and modulate cholinergic synaptic number in vivo.
Debeir T; Saragovi HU; Cuello AC
J Physiol Paris; 1998; 92(3-4):205-8. PubMed ID: 9789809
[TBL] [Abstract][Full Text] [Related]
30. Signalling events regulating the retrograde axonal transport of 125I-beta nerve growth factor in vivo.
Reynolds AJ; Bartlett SE; Hendry IA
Brain Res; 1998 Jul; 798(1-2):67-74. PubMed ID: 9666080
[TBL] [Abstract][Full Text] [Related]
31. Label-free and real-time cell-based kinase assay for screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array.
Atienza JM; Yu N; Wang X; Xu X; Abassi Y
J Biomol Screen; 2006 Sep; 11(6):634-43. PubMed ID: 16858006
[TBL] [Abstract][Full Text] [Related]
32. Novel class of pain drugs based on antagonism of NGF.
Hefti FF; Rosenthal A; Walicke PA; Wyatt S; Vergara G; Shelton DL; Davies AM
Trends Pharmacol Sci; 2006 Feb; 27(2):85-91. PubMed ID: 16376998
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and kinase inhibitory activity of 3'-(S)-epi-K-252a.
Gingrich DE; Hudkins RL
Bioorg Med Chem Lett; 2002 Oct; 12(20):2829-31. PubMed ID: 12270156
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition.
Bernard-Gauthier V; Schirrmacher R
Expert Opin Ther Pat; 2016; 26(2):291-5. PubMed ID: 26561352
[TBL] [Abstract][Full Text] [Related]
35. [Studies on the action mechanism of gossypol with fixed concentration radioactive-ligand receptor assay].
Ye YX; Zheng YJ; Bi XF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1986 Apr; 8(2):96-9. PubMed ID: 2944651
[No Abstract] [Full Text] [Related]
36. Kinase receptor activation (KIRA): a rapid and accurate alternative to end-point bioassays.
Sadick MD; Intintoli A; Quarmby V; McCoy A; Canova-Davis E; Ling V
J Pharm Biomed Anal; 1999 May; 19(6):883-91. PubMed ID: 10698554
[TBL] [Abstract][Full Text] [Related]
37. Immunoprecipitation method for a radioligand binding assay of epidermal growth factor receptor.
Dittadi R; Gion M; Brazzale A; Bruscagnin G
J Nucl Med Allied Sci; 1990; 34(4 Suppl):225-30. PubMed ID: 2092123
[No Abstract] [Full Text] [Related]
38. Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple.
Krohn KA; Link JM
Nucl Med Biol; 2003 Nov; 30(8):819-26. PubMed ID: 14698785
[TBL] [Abstract][Full Text] [Related]
39. [Establishment of a new method for insulin antibody measurement by antibody beads].
Sato M; Hashimoto F; Ooboshi C; Hirota M; Oshima I; Shima K
Rinsho Byori; 1987 May; 35(5):582-6. PubMed ID: 3613169
[No Abstract] [Full Text] [Related]
40. [A rapid graphic method for the informative determination of affinity relations and percentual representation of 2 different receptor subtypes reacting with 1 radioactive ligand].
Wenke M; Schindler J; Hynie S
Cesk Fysiol; 1984; 33(2):123-9. PubMed ID: 6722924
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
